Risk Paradigm Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Risk Paradigm Group’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,650	Closed	-$77K	–	113
2018 Q1	$77K	Buy	2,650 +700	+36%	+$19.8K	0.1%	126
2017 Q4	$46.4K	Buy	+1,950	New	+$49.3K	0.05%	164
2017 Q3	–	Sell	-700	Closed	-$16.1K	–	237
2017 Q2	$16.1K	Buy	+700	New	+$15.8K	0.02%	204

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Risk Paradigm Group's CNCR Position: Q2 2018 in Review

Risk Paradigm Group sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2018, closing a stake of 2,650 shares — an estimated $77K sold.

Risk Paradigm Group first reported a position in CNCR in Q2 2017 and held it in 3 quarters. The position peaked at $77K in Q1 2018. 28 funds tracked by Wall St. Rank hold CNCR as of Q2 2018.

Risk Paradigm Group reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2018 after selling out during the quarter.
Risk Paradigm Group sold 2,650 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2018, an estimated $77K.
Risk Paradigm Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2017 and held it in 3 quarters.
Risk Paradigm Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $77K in Q1 2018.
28 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2018.

Based on Risk Paradigm Group's 13F filing for Q2 2018, filed 10 Aug 2018.